[
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=c716a8e2e09be47489c5705508333759850deddb0a2892ec78e84566bf77df5e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743438660,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 133636195,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=c716a8e2e09be47489c5705508333759850deddb0a2892ec78e84566bf77df5e"
    }
  },
  {
    "ts": null,
    "headline": "Best Dividend Aristocrats For April 2025",
    "summary": "Dividend Aristocrats in 2025 show resilience, outperforming the S&P 500. Click here to read what investors need to know.",
    "url": "https://finnhub.io/api/news?id=8d2f7e6be3053b554cc8ee87405abf96ff95f26b38f72e7f7cdf82cef0d639bd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743437243,
      "headline": "Best Dividend Aristocrats For April 2025",
      "id": 133629387,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2165465384/image_2165465384.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Dividend Aristocrats in 2025 show resilience, outperforming the S&P 500. Click here to read what investors need to know.",
      "url": "https://finnhub.io/api/news?id=8d2f7e6be3053b554cc8ee87405abf96ff95f26b38f72e7f7cdf82cef0d639bd"
    }
  },
  {
    "ts": null,
    "headline": "Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst",
    "summary": "Sellas Life Sciences Group, Inc.'s Phase 3 GPS trial sparks uncertainty; stock's a Hold. Interim results for GPS are promising but iffy. Click for more on SLS.",
    "url": "https://finnhub.io/api/news?id=51527034d54832664ecb25a4ad637bcb2d030897e5c8f5b0330cebbecd4ff002",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743433428,
      "headline": "Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst",
      "id": 133629058,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/487041745/image_487041745.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Sellas Life Sciences Group, Inc.'s Phase 3 GPS trial sparks uncertainty; stock's a Hold. Interim results for GPS are promising but iffy. Click for more on SLS.",
      "url": "https://finnhub.io/api/news?id=51527034d54832664ecb25a4ad637bcb2d030897e5c8f5b0330cebbecd4ff002"
    }
  },
  {
    "ts": null,
    "headline": "MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon…",
    "summary": "By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Data Expected in April 2025 from Part 2 of Phase 1 Trial of DA-1726 MetaVia Inc. (NASDAQ:MTVA) is currently conducting a Phase 1 clinical trial of DA-1726 in patients with obesity. In September 2024, MetaVia announced positive topline results for the single ascending dose (SAD) Part 1 of the trial. A total of 45",
    "url": "https://finnhub.io/api/news?id=39e7206939be6abc977a17b984b67022b97533a215400b47233df1e3e262b275",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743430560,
      "headline": "MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon…",
      "id": 133632964,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Data Expected in April 2025 from Part 2 of Phase 1 Trial of DA-1726 MetaVia Inc. (NASDAQ:MTVA) is currently conducting a Phase 1 clinical trial of DA-1726 in patients with obesity. In September 2024, MetaVia announced positive topline results for the single ascending dose (SAD) Part 1 of the trial. A total of 45",
      "url": "https://finnhub.io/api/news?id=39e7206939be6abc977a17b984b67022b97533a215400b47233df1e3e262b275"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to Host First-Quarter 2025 Earnings Conference Call",
    "summary": "AbbVie (NYSE: ABBV) will announce its first-quarter 2025 financial results on Friday, April 25, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.",
    "url": "https://finnhub.io/api/news?id=1cf5ac23b958b339231d47b64025dbdc0c415a9ebee8a723a9b4209083aa1f98",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743422400,
      "headline": "AbbVie to Host First-Quarter 2025 Earnings Conference Call",
      "id": 133625658,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) will announce its first-quarter 2025 financial results on Friday, April 25, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.",
      "url": "https://finnhub.io/api/news?id=1cf5ac23b958b339231d47b64025dbdc0c415a9ebee8a723a9b4209083aa1f98"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Margin Expansion Potential Can Support Elevated P/E",
    "summary": "AbbVie Inc. is a solid hold despite Humira sales decline. Explore growth opportunities in Skyrizi, Rinvoq, and the obesity drug market. Click for our ABBV update.",
    "url": "https://finnhub.io/api/news?id=aeb675b1415216e9da8efc00422b23e4968adbb1c41e8cae021d62deb58d8614",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743416410,
      "headline": "AbbVie: Margin Expansion Potential Can Support Elevated P/E",
      "id": 133626593,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2161348087/image_2161348087.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc. is a solid hold despite Humira sales decline. Explore growth opportunities in Skyrizi, Rinvoq, and the obesity drug market. Click for our ABBV update.",
      "url": "https://finnhub.io/api/news?id=aeb675b1415216e9da8efc00422b23e4968adbb1c41e8cae021d62deb58d8614"
    }
  },
  {
    "ts": null,
    "headline": "PGIM Jennison Value Fund Q4 2024 Commentary",
    "summary": "The PGIM Jennison Value Fund advanced and outperformed the Russell 1000 Value Index during Q4 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=278d9829a07c13d3f4771e964b3454bce1732917eeb089344861f85d222c734f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743414300,
      "headline": "PGIM Jennison Value Fund Q4 2024 Commentary",
      "id": 133626380,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2163730037/image_2163730037.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The PGIM Jennison Value Fund advanced and outperformed the Russell 1000 Value Index during Q4 2024. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=278d9829a07c13d3f4771e964b3454bce1732917eeb089344861f85d222c734f"
    }
  },
  {
    "ts": null,
    "headline": "Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.",
    "summary": "Building a retirement portfolio of $1 million or more is within reach for many Americans.  AbbVie (NYSE: ABBV) is a great example of a company that has proved such a capability.  A few years ago, some wondered what would happen to AbbVie after key patents expired for Humira, the company's top-selling drug.",
    "url": "https://finnhub.io/api/news?id=88a1049a8166e936685e8f3c537f1bbec3e4d39dc3706d72d0fb2eeab2a805f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743411180,
      "headline": "Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.",
      "id": 133625659,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Building a retirement portfolio of $1 million or more is within reach for many Americans.  AbbVie (NYSE: ABBV) is a great example of a company that has proved such a capability.  A few years ago, some wondered what would happen to AbbVie after key patents expired for Humira, the company's top-selling drug.",
      "url": "https://finnhub.io/api/news?id=88a1049a8166e936685e8f3c537f1bbec3e4d39dc3706d72d0fb2eeab2a805f7"
    }
  }
]